Barinthus Biotherapeutics plc (BRNS)
Official siteHEALTHCARE • BIOTECHNOLOGY • PINK
Market Cap: $30.23M
Last updated: Nov 16, 2026 at 4:00 PM ET
Barinthus Biotherapeutics plc (BRNS) Statistics
Barinthus Biotherapeutics (BRNS) has a market cap of $30.23M. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $30.23M |
|---|---|
| Close (Nov 16, 2026) | $0.74 |
Key Dates
The next earnings report is expected on Mar 11, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 11, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 6, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 0.5x |
|---|---|
| P/TBV Ratio | 0.7x |
Price Statistics
The stock is down 5.36% over 52 weeks and trades at its 50-day average.
| Beta (1Y) | 0.73 |
|---|---|
| 52-Week Change | -5.36% |
| 3-Month Change | +19.37% |
| 6-Month Change | +15.91% |
| 5-Year Change | -94.64% |
| Total Return (1Y) | -5.36% |
| Total Return (3Y CAGR) | -35.46% |
| Total Return (5Y CAGR) | -43.46% |
| Max Drawdown (1Y) | -32.06% |
| Max Drawdown (3Y) | -85.40% |
| Sharpe Ratio (1Y) | 0.06 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $0.74 |
| 200-Day Average | $0.66 |
| 52-Week Range | $0.51 to $0.85 |
| RSI (14 Days) | 60.3 |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.54x current liabilities.
| Current Ratio | 5.54x |
|---|---|
| Quick Ratio | 5.54x |
| Interest Coverage | -796.09x |
Returns and Efficiency
Return on equity is -73.14% over the last 12 months, against a 5-year average of -38.79%.
| Return on Equity (ROE) | -73.14% |
|---|---|
| Return on Assets (ROA) | -50.97% |
| Return on Capital Employed (ROCE) | -59.83% |
| ROE (5Y Average) | -38.79% |
| ROA (5Y Average) | -31.25% |
| ROIC (5Y Average) | -38.28% |
Scores
BRNS has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$44.60M |
| Pretax Income | -$42.21M |
| Net Income | -$41.74M |
| EBITDA | -$38.67M |
| EBIT | -$42.16M |
| Reported EPS (TTM) | -$0.91 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 69.69% of the $81.89M in total assets.
| Cash and Equivalents | $59.30M |
|---|---|
| Working Capital | $51.85M |
| Shareholder Equity | $57.07M |
| Tangible Book Value | $44.03M |
| Total Assets | $81.89M |
| Total Liabilities | $24.76M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $234 of capital spending, operating cash flow left -$26.43M of free cash flow.
| Operating Cash Flow | -$26.43M |
|---|---|
| Capital Expenditures | $234 |
| Free Cash Flow | -$26.43M |
| FCF Per Share | -$0.65 |
| Depreciation and Amortization | $3.49M |
Trailing 12 months through Jun 30, 2026.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BRNS
What is BRNS's market cap?
Barinthus Biotherapeutics has a market cap of $30.23M.
How many shares of BRNS are outstanding?
Barinthus Biotherapeutics has 40.85M shares outstanding. The count is up 1.25% from a year earlier.
Does BRNS pay a dividend?
No. Barinthus Biotherapeutics does not pay a dividend.
BRNS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors